Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean Pierre Delord

Showing results (11-20 of 178) with videos related to

Pageof 18
Sort By:
Expert Opinion on Investigational Drugs|September 28, 2005
Vinflunine: a novel antitubulin agent in solid malignanciesJaafar Bennouna, Mario Campone, Jean Pierre Delord, et al.
Bulletin Du Cancer|June 3, 2004
[Demography of oncologic practitioners working in France. Projection elements for the next 30 years]P Rivera, Jean-Pierre Delord, P Grosclaude, et al.
Springerplus|January 4, 2014
Cystadenocarcinoma of the parotid: case report of a BRAF inhibitor treatmentSabrina Boyrie, Isabelle Fauquet, Michel Rives, et al.
Revue De L'Infirmiere|September 15, 2015
[Nurse telephone support at home during chemotherapy]Frédéric Despiau, Marie Bombail, Céline Leches, et al.
Surgical Oncology|March 2, 2010
Peritoneal pseudomyxoma arising from the urachusAlejandra Martínez, Gwénael Ferron, Eliane Mery, et al.
Current Opinion in Oncology|May 3, 2016
Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodiesVincent Sibaud, Nicolas Meyer, Laurence Lamant, et al.
Cancer Chemotherapy and Pharmacology|December 6, 2005
Phase-I study of a new schedule based on increasing days of topotecan administration associated with dose individualisationJean-Pierre Delord, Frédéric Léger, Pierre Canal, et al.
Bulletin Du Cancer|November 13, 2022
5-fluorouracil with oxaliplatin and/or irinotecan for advanced sinonasal intestinal-type adenocarcinoma (ITAC)Victor Sarradin, Sarah Betrian, Léonor Chaltiel, et al.
Therapie|October 1, 2014
[Cetuximab cutaneous adverse drug reactions: a marker of efficacy for metastatic colorectal cancer and head-neck cancer?]Marlène Soussan-Dahan, Maryse Lapeyre-Mestre, Emmanuelle Bondon-Guitton, et al.
Clinical Pharmacokinetics|April 5, 2012
Vinflunine oral pharmacokinetics and absolute bioavailability of soft and hard gelatin capsules: results of two phase I trialsJean-Pierre Delord, Jaafar Bennouna, Loïc Mourey, et al.
Pageof 18

Showing results (11-20 of 178) with videos related to

Sort By:
Pageof 18
Expert Opinion on Investigational Drugs|September 28, 2005
Vinflunine: a novel antitubulin agent in solid malignanciesJaafar Bennouna, Mario Campone, Jean Pierre Delord, et al.
Bulletin Du Cancer|June 3, 2004
[Demography of oncologic practitioners working in France. Projection elements for the next 30 years]P Rivera, Jean-Pierre Delord, P Grosclaude, et al.
Springerplus|January 4, 2014
Cystadenocarcinoma of the parotid: case report of a BRAF inhibitor treatmentSabrina Boyrie, Isabelle Fauquet, Michel Rives, et al.
Revue De L'Infirmiere|September 15, 2015
[Nurse telephone support at home during chemotherapy]Frédéric Despiau, Marie Bombail, Céline Leches, et al.
Surgical Oncology|March 2, 2010
Peritoneal pseudomyxoma arising from the urachusAlejandra Martínez, Gwénael Ferron, Eliane Mery, et al.
Current Opinion in Oncology|May 3, 2016
Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodiesVincent Sibaud, Nicolas Meyer, Laurence Lamant, et al.
Cancer Chemotherapy and Pharmacology|December 6, 2005
Phase-I study of a new schedule based on increasing days of topotecan administration associated with dose individualisationJean-Pierre Delord, Frédéric Léger, Pierre Canal, et al.
Bulletin Du Cancer|November 13, 2022
5-fluorouracil with oxaliplatin and/or irinotecan for advanced sinonasal intestinal-type adenocarcinoma (ITAC)Victor Sarradin, Sarah Betrian, Léonor Chaltiel, et al.
Therapie|October 1, 2014
[Cetuximab cutaneous adverse drug reactions: a marker of efficacy for metastatic colorectal cancer and head-neck cancer?]Marlène Soussan-Dahan, Maryse Lapeyre-Mestre, Emmanuelle Bondon-Guitton, et al.
Clinical Pharmacokinetics|April 5, 2012
Vinflunine oral pharmacokinetics and absolute bioavailability of soft and hard gelatin capsules: results of two phase I trialsJean-Pierre Delord, Jaafar Bennouna, Loïc Mourey, et al.
Pageof 18